Date: 2014-05-08
Type of information: Licensing agreement
Compound: intellectual property (IP) relating to the CRISPR/Cas9 gene editing system
Company: Horizon Discovery (UK) ERS Genomics (Ireland)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On May 8, 2014, Horizon Discovery™ Group, the international life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines, announced it has entered into a non-exclusive license agreement with ERS Genomics Ltd to access intellectual property (IP) relating to the CRISPR/Cas9 gene editing system. Under the terms of the agreement, Horizon has rights to use the technology, which is based on the work of Dr. Emmanuelle Charpentier and her colleagues, for research applications including development and sale of research tools, kits and reagents, performance of research services, creation of genetically modified disease model cell lines, development and production of reference standard material for molecular diagnostics and for internal target identification and validation research efforts. The acquisition of this important CRISPR IP is in line with the Company’s aims outlined at the time of its IPO and further strengthens Horizon’s long-term position in the market for this cutting edge gene editing technology. Access to a broader CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D and further enhance the attractiveness of the Horizon GENESIS™ offering to customers.
Financial terms:
Latest news:
